Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals Drug

Daiichi Sankyo Enlists Innovent Biologics as Exclusive China Partner for Vanflyta FLT3 Inhibitor in AML

Fineline Cube Aug 10, 2026
Company Deals

Transcenta and WuXi Biologics Forge Strategic CDMO Partnership with RMB 190 Million Manufacturing Facility Transaction

Fineline Cube Aug 7, 2026
Company Deals

Biogen Completes $1 Billion Acquisition of RayThera to Bolster Immunology Portfolio with Novel Small-Molecule Pipeline

Fineline Cube Aug 7, 2026
Company Deals

Syndax Terminates Entinostat License Agreement with EOC HK, Ending Jingzhuda Commercial Rights in China

Fineline Cube Aug 6, 2026
Company Deals

AstraZeneca and CSPC Pharmaceutical Establish Joint Venture for Next-Generation Biologics Manufacturing Base in Shijiazhuang

Fineline Cube Aug 6, 2026
Policy / Regulatory

China’s CDE Releases 109th Reference Listed Drug Catalog, Adding 10 New Generic Drug Specifications

Fineline Cube Aug 6, 2026
Company Drug

Salubris’s SAL0195 siRNA Drug Wins NMPA Nod for Lp(a) Clinical Trials

Fineline Cube Aug 10, 2026
Company Drug

Grand Pharma’s GPN01530-2 RDC Drug Snags FDA Fast Track for Solid Tumor Diagnosis

Fineline Cube Aug 10, 2026
Company Medical Device

Blue Sail Medical Enrolls First Patient in Study for Rapamycin-Coated Balloon Catheter

Fineline Cube Oct 24, 2023

China’s Blue Sail Medical Co., Ltd (SHE: 002382) has announced a significant milestone with the...

Company Drug

Transcenta Holdings Unveils Updated Osemitamab Data in Advanced Gastric Cancer at ESMO

Fineline Cube Oct 24, 2023

China-based biotech Transcenta Holdings Ltd (HKG: 6628) has presented updated efficacy data from the expansion...

Company Drug

Vcanbio Receives NMPA Approval for Clinical Study of VUM02 in SR-aGvHD Treatment

Fineline Cube Oct 24, 2023

China-based biotechnology firm Vcanbio Cell & Gene Engineering Corp., Ltd (SHA: 600645) has announced that...

Company Deals

Roche Agrees to Acquire Telavant for $7.1 Billion to Boost IBD Treatment Portfolio

Fineline Cube Oct 24, 2023

Switzerland-headquartered pharmaceutical giant Roche (SWX: ROG) announced this week an agreement to purchase Telavant Holdings,...

Company Deals

J&J MedTech Partners with CED Medical for Neurointerventional Solutions

Fineline Cube Oct 24, 2023

Johnson & Johnson MedTech’s (J&J, NYSE: JNJ) Shanghai-based subsidiary, Johnson Johnson Medical Equipment Co., Ltd,...

Company Drug

Alphamab Oncology Presents Promising Data for KN046 and KN026 at ESMO 2023

Fineline Cube Oct 24, 2023

China-based Alphamab Oncology (HKG: 9966) has released data snapshots from clinical studies for two of...

Company Drug

Janssen’s TAR-200 Shows High Complete Response Rate in Bladder Cancer Study

Fineline Cube Oct 23, 2023

Johnson & Johnson (J&J; NYSE: JNJ) subsidiary Janssen has published data from a Phase IIb...

Company Drug

Novartis’ Kisqali Plus Endocrine Therapy Shows Improved Survival in Early Breast Cancer Study

Fineline Cube Oct 23, 2023

Switzerland-based pharmaceutical company Novartis (NYSE: NVS) has announced additional results from an ongoing Phase III...

Company

Boehringer Ingelheim Appoints Mohammed Tawil as New CEO for Greater China Region

Fineline Cube Oct 23, 2023

Germany’s Boehringer Ingelheim (BI) has announced a leadership transition within its Greater China region, which...

Company Drug

Pfizer’s Penbraya Receives FDA Approval for Meningococcal Immunization

Fineline Cube Oct 23, 2023

Pfizer Inc. (NYSE: PFE) announced last week that it has successfully registered its pentavalent meningococcal...

Policy / Regulatory

National VBP Tender Program Invites Drugs Approved Before October 30 for Round 9

Fineline Cube Oct 23, 2023

The National Allied Procurement Office has released a notification regarding Round 9 of the national...

Company Deals

MSD Cancels Development of Two Pre-Clinical ADCs from Sichuan Kelun-Biotech

Fineline Cube Oct 23, 2023

China-based Sichuan Kelun Pharmaceutical Co., Ltd (SHE: 002422) and its innovative drug development subsidiary Sichuan...

Company Drug

Health Canada Approves Pfizer and Sumitomo Pharma’s Myfembree for Endometriosis Pain Management

Fineline Cube Oct 23, 2023

Health Canada has granted regulatory approval to Pfizer (NYSE: PFE) and Sumitomo Pharma (TYO: 4506)...

Company

Shanghai Henlius Receives GMP Certification from ANVISA for Biosimilar Manufacturing

Fineline Cube Oct 23, 2023

China-based Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) subsidiary Shanghai Henlius Biotech,...

Company Drug

Shanghai Fudan-Zhangjiang’s ADC FZ-AD005 Accepted for NMPA Review in Advanced Solid Tumors

Fineline Cube Oct 23, 2023

China-based Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd (HKG: 1349; SHA: 688505) has announced that the National...

Company Deals

AcuVu Medical Partners with Hologic for US Distribution of HummingScope Hysteroscopy System

Fineline Cube Oct 23, 2023

AcuVu Medical, a specialist in electronic endoscopes with operations in California, USA, and Suzhou, China,...

Company Deals

CBC HIP Secures USD 875 Million for Life Science Real Assets Venture CLSRA

Fineline Cube Oct 23, 2023

CBC Healthcare Infrastructure Platform (CBC HIP), a prominent independent life science real assets investor in...

Company Drug

BeiGene’s Brukinsa Gains NICE Recommendation for CLL Treatment in the UK

Fineline Cube Oct 23, 2023

China-based biotech BeiGene Ltd (NASDAQ: BGNE; HKG: 6160; SHA: 688235) has announced that the National...

Company Drug

Jacobio Pharma’s Glecirasib Combo Shows Promising Results in ESMO Congress 2023 Presentation

Fineline Cube Oct 23, 2023

China-based Jacobio Pharma (HKG: 1167) has presented clinical data for its KRAS G12C inhibitor glecirasib...

Company Deals

Hotgen Biotech Partners with Genoval Therapeutics for RNAi Drug Development

Fineline Cube Oct 23, 2023

China’s Hotgen Biotech Co., Ltd (SHA: 688068) has announced a strategic partnership between its anti-aging...

Posts pagination

1 … 495 496 497 … 705

Recent updates

  • Salubris’s SAL0195 siRNA Drug Wins NMPA Nod for Lp(a) Clinical Trials
  • Grand Pharma’s GPN01530-2 RDC Drug Snags FDA Fast Track for Solid Tumor Diagnosis
  • Alebund’s AP301 NDA Accepted by NMPA for Hyperphosphatemia in CKD Dialysis Patients
  • Sino Biopharma’s benmelstobart-anlotinib Combo Wins NMPA Nod for First-Line sq-NSCLC
  • Hybio Files First tirzepatide Generic ANDA in China, Challenging Eli Lilly’s GLP-1 Dominance
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Salubris’s SAL0195 siRNA Drug Wins NMPA Nod for Lp(a) Clinical Trials

Company Drug

Grand Pharma’s GPN01530-2 RDC Drug Snags FDA Fast Track for Solid Tumor Diagnosis

Company Drug

Alebund’s AP301 NDA Accepted by NMPA for Hyperphosphatemia in CKD Dialysis Patients

Company Drug

Sino Biopharma’s benmelstobart-anlotinib Combo Wins NMPA Nod for First-Line sq-NSCLC

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.